Dosing will be a key success factor in repurposing antivirals for COVID-19

摘要

As new treatment modalities are being explored for SARS-CoV-2, efforts to repurpose existing marketed drugs remain an attractive option, as these agents are readily available and have a known safety profile. It is important to recognize that these drugs have not been specifically developed or optimized for the treatment of SARS-CoV-2 infected patients. Success in repurposing efforts will depend on being mindful of first principles around clinical pharmacology and dosing strategies, noting that the dose regimens of existing drugs were developed for different indications.